Center Laboratories, Inc. (4123.TWO)
TWD 41.9
(-1.53%)
TWD 41.9
(-1.53%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -995.42 Million TWD | -82.0% |
| 2022 | -575.62 Million TWD | -131.69% |
| 2021 | 1.81 Billion TWD | -52.03% |
| 2020 | 3.78 Billion TWD | 1959.86% |
| 2019 | -203.58 Million TWD | -103.35% |
| 2018 | 6.08 Billion TWD | 2333.54% |
| 2017 | 249.99 Million TWD | 1185.01% |
| 2016 | 19.45 Million TWD | -95.38% |
| 2015 | 421.5 Million TWD | 26.48% |
| 2014 | 333.26 Million TWD | 541.99% |
| 2013 | 51.91 Million TWD | -48.01% |
| 2012 | 99.85 Million TWD | 134.64% |
| 2011 | 42.55 Million TWD | 228.26% |
| 2010 | 12.96 Million TWD | -90.63% |
| 2009 | 138.4 Million TWD | 204.45% |
| 2008 | 45.46 Million TWD | -60.35% |
| 2007 | 114.65 Million TWD | 647.22% |
| 2006 | 15.34 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -72.46 Million TWD | 86.6% |
| 2024 Q1 | -540.97 Million TWD | -514.13% |
| 2023 Q2 | -933.04 Million TWD | -194.09% |
| 2023 Q4 | -88.08 Million TWD | 91.0% |
| 2023 Q3 | -978.71 Million TWD | -4.89% |
| 2023 FY | -1.04 Billion TWD | -82.0% |
| 2023 Q1 | 991.63 Million TWD | 5546.48% |
| 2022 Q3 | -1.21 Billion TWD | -422.52% |
| 2022 Q2 | -231.75 Million TWD | -127.28% |
| 2022 Q4 | 17.56 Million TWD | 101.45% |
| 2022 FY | -575.62 Million TWD | -131.69% |
| 2022 Q1 | 849.54 Million TWD | 220.03% |
| 2021 FY | 1.81 Billion TWD | -52.03% |
| 2021 Q3 | -813.42 Million TWD | -166.71% |
| 2021 Q4 | -707.79 Million TWD | 12.99% |
| 2021 Q2 | 1.21 Billion TWD | -42.43% |
| 2021 Q1 | 2.11 Billion TWD | 54.15% |
| 2020 Q4 | 1.37 Billion TWD | 44.99% |
| 2020 Q3 | 947.73 Million TWD | -24.48% |
| 2020 Q2 | 1.25 Billion TWD | 498.42% |
| 2020 FY | 3.78 Billion TWD | 1959.86% |
| 2020 Q1 | 209.7 Million TWD | 252.65% |
| 2019 FY | -203.58 Million TWD | -103.35% |
| 2019 Q2 | 35.46 Million TWD | 116.54% |
| 2019 Q3 | 29.9 Million TWD | -15.67% |
| 2019 Q4 | -137.38 Million TWD | -559.41% |
| 2019 Q1 | -214.38 Million TWD | -105.47% |
| 2018 Q2 | 137.15 Million TWD | -69.29% |
| 2018 FY | 6.08 Billion TWD | 2333.54% |
| 2018 Q4 | 3.91 Billion TWD | 147.59% |
| 2018 Q3 | 1.58 Billion TWD | 1053.71% |
| 2018 Q1 | 446.62 Million TWD | 85.39% |
| 2017 Q4 | 240.91 Million TWD | 373.61% |
| 2017 FY | 249.99 Million TWD | 1185.01% |
| 2017 Q2 | -20.82 Million TWD | 0.7% |
| 2017 Q3 | 50.86 Million TWD | 344.32% |
| 2017 Q1 | -20.96 Million TWD | 71.31% |
| 2016 Q4 | -73.07 Million TWD | -135.62% |
| 2016 FY | 19.45 Million TWD | -95.38% |
| 2016 Q3 | 205.16 Million TWD | 483.32% |
| 2016 Q2 | -53.52 Million TWD | 9.45% |
| 2016 Q1 | -59.1 Million TWD | -109.68% |
| 2015 FY | 421.5 Million TWD | 26.48% |
| 2015 Q1 | -74.8 Million TWD | -123.1% |
| 2015 Q3 | -8.2 Million TWD | 92.26% |
| 2015 Q4 | 610.5 Million TWD | 7541.53% |
| 2015 Q2 | -105.98 Million TWD | -41.68% |
| 2014 Q3 | -121.48 Million TWD | -207.47% |
| 2014 FY | 333.26 Million TWD | 541.99% |
| 2014 Q4 | 323.86 Million TWD | 366.58% |
| 2014 Q2 | 113.04 Million TWD | 533.32% |
| 2014 Q1 | 17.84 Million TWD | -41.68% |
| 2013 Q3 | 54.67 Million TWD | 281.84% |
| 2013 FY | 51.91 Million TWD | -48.01% |
| 2013 Q1 | -3.29 Million TWD | -102.97% |
| 2013 Q2 | -30.06 Million TWD | -811.46% |
| 2013 Q4 | 30.6 Million TWD | -44.03% |
| 2012 Q4 | 111.02 Million TWD | 1227.61% |
| 2012 FY | 99.85 Million TWD | 134.64% |
| 2012 Q1 | 59 Thousand TWD | -99.4% |
| 2012 Q2 | -19.44 Million TWD | -33059.32% |
| 2012 Q3 | 8.36 Million TWD | 143.01% |
| 2011 Q3 | 6.28 Million TWD | 475.02% |
| 2011 Q4 | 9.83 Million TWD | 56.44% |
| 2011 FY | 42.55 Million TWD | 228.26% |
| 2011 Q1 | 25.34 Million TWD | 2402.07% |
| 2011 Q2 | 1.09 Million TWD | -95.69% |
| 2010 Q1 | 4.21 Million TWD | 0.0% |
| 2010 Q2 | 7.2 Million TWD | 70.8% |
| 2010 Q4 | 1.01 Million TWD | 92.59% |
| 2010 FY | 12.96 Million TWD | -90.63% |
| 2010 Q3 | 526 Thousand TWD | -92.7% |
| 2009 FY | 138.4 Million TWD | 204.45% |
| 2008 FY | 45.46 Million TWD | -60.35% |
| 2007 FY | 114.65 Million TWD | 647.22% |
| 2006 FY | 15.34 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Allied Biotech Corporation | 97.41 Million TWD | 1121.867% |
| GeneFerm Biotechnology Co., Ltd. | 124.62 Million TWD | 898.759% |
| Easywell Biomedicals, Inc. | -144.81 Million TWD | -587.36% |
| TTY Biopharm Company Limited | 1.12 Billion TWD | 188.207% |
| Synmosa Biopharma Corporation | 594.83 Million TWD | 267.345% |
| Orient EuroPharma Co., Ltd. | 143.94 Million TWD | 791.538% |
| Tien Liang BioTech Co., Ltd. | 17.73 Million TWD | 5713.698% |
| Orient Pharma Co., Ltd. | 22.28 Million TWD | 4566.175% |
| InnoPharmax Inc. | -70.83 Million TWD | -1305.347% |
| Johnson Chemical Pharmaceutical Works Co., Ltd. | 79.7 Million TWD | 1348.96% |
| Excelsior Biopharma Inc. | -91.01 Million TWD | -993.737% |
| DV Biomed Co., Ltd. | 162.91 Million TWD | 711.025% |
| Foresee Pharmaceuticals Co., Ltd. | -1.03 Billion TWD | 3.945% |
| Handa Pharmaceuticals, Inc. | 726.88 Million TWD | 236.943% |
| UniPharma Co., Ltd. | -21.81 Million TWD | -4463.43% |
| Anxo Pharmaceutical Co., Ltd. | 21.86 Million TWD | 4653.41% |
| Alar Pharmaceuticals Inc. | 382.61 Million TWD | 360.162% |
| Winston Medical Supply Co., Ltd. | 158.75 Million TWD | 727.017% |
| Mercury Biopharmaceutical Corporation | -43.81 Million TWD | -2171.821% |
| Bioray Biotech Co., Ltd | -11.55 Million TWD | -8511.653% |
| TSH Biopharm Corporation Limited | 61.98 Million TWD | 1705.803% |